From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis
Abstract: This retrospective analysis examined 15 years of autologous stem cell transplantation (ASCT) for light chain (AL) amyloidosis at the Mayo Clinic (2010-2024). We aimed to assess ASCT utilization trends, factors influencing practice changes, and current indications amid newer therapies. Four...
Saved in:
| Main Authors: | Eli Muchtar, Angela Dispenzieri, Francis K. Buadi, Prashant Kapoor, David Dingli, Taxiarchis V. Kourelis, Wilson Gonsalves, Nelson Leung, Suzanne R. Hayman, Martha Q. Lacy, Mustaqeem Siddiqui, Joselle Cook, Nadine Abdallah, Moritz Binder, Saurabh Zanwar, William Hogan, Rahma Warsame, S. Vincent Rajkumar, Shaji K. Kumar, Morie A. Gertz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925003672 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation
by: Gréta Garami, et al.
Published: (2025-01-01) -
Daratumumab‐based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case‐control study
by: Claudia Bellofiore, et al.
Published: (2025-03-01) -
Bor
by: Blagica Stanoeska
Published: (2025-07-01) -
Bor
by: Blagica Stanoeska
Published: (2025-07-01) -
TOPRAKLARDA BOR ADSORPSİYONU
by: Sonay Sözüdoğru, et al.
Published: (1996-01-01)